- Conditions
- Fabry Disease
- Interventions
- migalastat HCl 150 mg
- Drug
- Lead sponsor
- Amicus Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 7
- States / cities
- Atlanta, Georgia • Kansas City, Kansas • Grand Rapids, Michigan + 4 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 817–840
of 2,082
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Eosinophils, Asthma
- Interventions
- reslizumab
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 391 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Bakersfield, California • Huntington Beach, California + 31 more
- Conditions
- Anemia
- Interventions
- Ferric Carboxymaltose (FCM)
- Drug
- Lead sponsor
- American Regent, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 145 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- Norristown, Pennsylvania
- Conditions
- Hypertrophic Cardiomyopathy
- Interventions
- mavacamten
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 4
- States / cities
- Scottsdale, Arizona • New Haven, Connecticut • Durham, North Carolina + 1 more
- Conditions
- Parkinson Disease
- Interventions
- CREXONT ER
- Drug
- Lead sponsor
- Impax Laboratories, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 27
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Aliso Viejo, California + 22 more
- Conditions
- Multiple Myeloma
- Interventions
- Oprozomib, Lenalidomide, Dexamethasone, Cyclophosphamide
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 14
- States / cities
- Huntsville, Alabama • Burbank, California • Los Angeles, California + 11 more
- Conditions
- Acute Gouty Arthritis Flares
- Interventions
- ACZ885, Triamcinolone acetonide 40 mg
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 33
- States / cities
- Anniston, Alabama • Mobile, Alabama • Norwalk, California + 28 more
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
- Interventions
- Bifeprunox
- Drug
- Lead sponsor
- Solvay Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 55 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- Orange, California
- Conditions
- Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia
- Interventions
- Blinatumomab, Extension of LTFU as per ProtocolAmendment7 7Jun18
- Drug · Other
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 0 Years to 17 Years
- U.S. locations
- 4
- States / cities
- Aurora, Colorado • Cincinnati, Ohio • Memphis, Tennessee + 1 more
- Conditions
- Intractable Pain, Neoplasms
- Interventions
- NP2, Placebo
- Biological
- Lead sponsor
- Diamyd Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 18
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Corona, California + 15 more
- Conditions
- Multiple Sclerosis, Walking Impairment
- Interventions
- ADS-5102, 274 mg
- Drug
- Lead sponsor
- Adamas Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 424 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 82
- States / cities
- Cullman, Alabama • Phoenix, Arizona • Tucson, Arizona + 75 more
- Conditions
- Hepatitis B, Chronic
- Interventions
- IMC-I109V Single Ascending Dose, IMC-I109V Multiple Ascending Doses, HBV HCC Module MAD
- Drug
- Lead sponsor
- Immunocore Ltd
- Industry
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Cleveland, Ohio
- Conditions
- Kidney Diseases, Kidney Diseases, Chronic, Urological Diseases, Glomerulonephritis, Glomerular Disease, Glomerulonephritis, IGA, Glomerulopathy, Immunoglobulin Disease
- Interventions
- zigakibart
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 8
- States / cities
- Denver, Colorado • Orlando, Florida • Iowa City, Iowa + 5 more
- Conditions
- Alopecia Areata
- Interventions
- Placebo Cream, Ruxolitinib Phosphate Cream
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Hot Springs, Arkansas • New Haven, Connecticut + 15 more
- Conditions
- Epilepsy With Simple or Complex Partial Onset Seizures
- Interventions
- Eslicarbazepine acetate
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 16 Years to 70 Years
- Enrollment
- 193 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 103
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Northport, Alabama + 82 more
- Conditions
- Major Depressive Disorder (MDD)
- Interventions
- SSRI (escitalopram or sertraline), Extended-Release Memantine, Placebo
- Drug
- Lead sponsor
- Jeffrey Miller
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Cutaneous Lupus Erythematosus (CLE)
- Interventions
- Quinacrine Hydrochloride, Placebo
- Drug · Other
- Lead sponsor
- Victoria Werth
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Healthy
- Interventions
- Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC], Canagliflozin 50 mg, Canagliflozin 100 mg, Metformin Extended Release (XR)
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Infantile Spasms
- Interventions
- Ganaxolone
- Drug
- Lead sponsor
- Marinus Pharmaceuticals
- Industry
- Eligibility
- 4 Months to 24 Months
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 14
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Miami, Florida + 10 more
- Conditions
- HIV-1-Infection
- Interventions
- ISL/LEN, Antiretroviral Combinations
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 49
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 41 more
- Conditions
- Long-chain Fatty Acid Oxidation Disorders (LC-FAOD), Carnitine Palmitoyltransferase (CPT II) Deficiency, Very Long Chain Acyl-CoA Dehydrogenase (VLCAD) Deficiency, Longchain 3-hydroxy-acyl-CoA Dehydrogenase (LCHAD) Deficiency, Trifunctional Protein (TFP) Deficiency
- Interventions
- UX007
- Drug
- Lead sponsor
- Ultragenyx Pharmaceutical Inc
- Industry
- Eligibility
- 6 Months and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 7
- States / cities
- Washington D.C., District of Columbia • Tampa, Florida • Chicago, Illinois + 4 more
- Conditions
- EDS, Cataplexy, Fatigue, Narcolepsy
- Interventions
- HBS-301, Placebo
- Drug · Other
- Lead sponsor
- Harmony Biosciences Management, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 258 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 51
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Peoria, Arizona + 46 more
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- Bendamustine, Obinutuzumab, Rituximab, Venetoclax
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 4
- States / cities
- La Jolla, California • Harvey, Illinois • Detroit, Michigan + 1 more
- Conditions
- Prostate Cancer
- Interventions
- SoluMatrix™ Abiraterone Acetate, Methylprednisolone
- Drug
- Lead sponsor
- GU Research Network, LLC
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 3
- States / cities
- Wichita, Kansas • Lincoln, Nebraska • Omaha, Nebraska